UK Markets close in 5 hrs 56 mins

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
25.600.00 (0.00%)
At close: 02:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close25.60
Open25.60
Bid0.00 x 0
Ask0.00 x 0
Day's range25.60 - 25.60
52-week range22.75 - 39.70
Volume100
Avg. volume11
Market cap428.319M
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents

    DGAP-News: ABIVAX / Key word(s): AGM/EGMABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents 18.05.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documentsPARIS, France, May 18, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX

  • EQS Group

    Abivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'

    DGAP-News: ABIVAX / Key word(s): Annual ReportAbivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel' 28.04.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax publishes Universal Registration Document 2022 "Document d'Enregistrement Universel"PARIS, France, April 28, 2022 - 6:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate th

  • EQS Group

    Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis

    DGAP-News: ABIVAX / Key word(s): Study results06.04.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464 Moreover, in the subgroup of patients who had at least a clinical res